Opus Genetics, Inc.'s SEC filings document financing, governance, capital-structure and operating disclosures for a Delaware clinical-stage biopharmaceutical company developing ophthalmic gene therapies. Form 8-K reports cover senior secured notes, preferred stock private placement activity, financial results, corporate presentations and compensatory arrangements.
Proxy materials and stockholder-vote reports cover director elections, auditor ratification, say-on-pay matters and amendments affecting authorized common stock. The filings also record corporate updates related to the company's inherited retinal disease pipeline and Phentolamine Ophthalmic Solution 0.75%.
Opus Genetics, Inc. (IRD) reporting person Foundation Fighting Blindness Retinal Degeneration Fund (RDF) sold 556,000 common shares on September 30, 2026, at a weighted average price of $4.9568 per share; multiple trades ranged from $4.95 to $5.29. RDF reported 3,236,171 shares following the sale. No Rule 10b5-1 plan is reported. The reporting persons may be deemed directors by deputization after Adrienne Graves, PhD and Jean Bennett, MD, PhD were appointed to Opus Genetics' board.
Opus Genetics, Inc. (IRD) reported that Chief Executive Officer and director George Magrath exercised a warrant for 392,157 shares of Common Stock on September 9, 2026 at an exercise price of $1.15 per share. The exercise was completed on a cashless basis, with 75,541 shares withheld to pay the exercise price and 316,616 shares issued to him. The warrant, which was immediately exercisable upon acquisition on March 24, 2025 and subject to specified stock-price and trading-volume call conditions, now shows no remaining derivative position in this filing.
Opus Genetics, Inc. (IRD) furnished a revised investor data presentation correcting an immaterial error in converting logMAR visual acuity to ETDRS letters for its Phase 1/2 OPGx-BEST1 Cohort 1 data. The corrected 3‑month letter changes per participant now range from a 12‑letter gain to a 10‑letter loss across treated eyes and from a 4‑letter gain to a 8‑letter loss in fellow eyes, and high‑resolution microperimetry images were added to the appendix.
The presentation highlights that in the low‑dose Cohort 1 (5 participants) OPGx‑BEST1 was well‑tolerated with no serious adverse events, no dose‑limiting toxicities, and no intraocular inflammation. Structural improvements were seen in 80% of participants, and all participants improved in at least one functional measure, with 75% of evaluable participants reaching the FDA‑aligned microperimetry threshold of ≥3 dB improvement in ≥5 loci. Cohort 2 (8 high‑dose participants) dosing is expected to complete in Q4 2026, with 3‑month topline data targeted for Q2 2027 and a pivotal trial planned to start dosing in 2027.
Opus reports a current cash runway extending into 2029, supporting OPGx‑BEST1 and four additional gene therapy programs through multiple anticipated clinical data readouts and milestones.
Opus Genetics, Inc. (IRD) reported interim 3‑ and 6‑month data from low‑dose Cohort 1 of its Phase 1/2 BIRD‑1 trial of gene therapy OPGx‑BEST1 in BEST1‑related retinal diseases. Five adults received 1.5 x 10⁹ vg/eye; all showed clinically meaningful improvement in at least one visual‑function measure, and four showed structural retinal improvements.
OPGx‑BEST1 was well tolerated, with no serious adverse events, dose‑limiting toxicities or intraocular inflammation; all treatment‑related events were mild or moderate. Functional gains included BCVA improvement in 60% of participants, and microperimetry improvements in 75% of evaluable participants, concentrated in the treated retinal transitional zone. Based on these proof‑of‑concept results, Opus has advanced to a higher‑dose Cohort 2 (4.5 x 10⁹ vg/eye), over‑enrolled to eight participants, with dosing expected to complete in Q4 2026 and topline three‑month data expected in Q2 2027. Following an August 2026 FDA Type C meeting, Opus and the FDA aligned on a potential pivotal endpoint using ≥3 dB microperimetry improvement in ≥5 prespecified loci with a patient‑reported outcome, and Opus expects to plan Phase 3 dosing in 2027. New research estimates about 23,600 symptomatic BEST1 patients in the U.S. and 45,400 globally, and the company states its cash runway extends into 2029.
Opus Genetics, Inc. (IRD) director Cam Gallagher exercised a warrant to acquire 784,314 shares of common stock on September 8, 2026 at an exercise price of $1.15 per share, converting a warrant that is now reported with zero remaining underlying shares.
Following this exercise, Gallagher directly holds 2,800,111 shares of common stock and also has an indirect position of 83,000 shares held as custodian for a minor under the Uniform Transfers to Minors Act, for which beneficial ownership is disclaimed except for any pecuniary interest. In connection with the warrant exercise, Gallagher entered into a Lock-Up Agreement dated September 6, 2026, agreeing not to transfer or dispose of common stock or related securities for 180 days after issuance of the exercised shares, subject to exclusions and with the issuer’s written consent requirement.
Opus Genetics, Inc. (IRD) reported that its Chief Financial Officer, Robert E. Gagnon, sold 28,000 shares of common stock on September 3, 2026. The weighted average sale price was $4.5433 per share, in multiple trades between $4.29 and $4.79, leaving him with 556,375 shares held directly. A portion of the shares was sold automatically to cover tax withholding from vesting restricted stock units, and the remainder was sold under a pre-arranged Rule 10b5-1 trading plan adopted on April 30, 2026.
Opus Genetics, Inc. (IRD) is the issuer for a planned sale of common stock under Rule 144 by officer Robert E. Gagnon28,000 shares of common stocktax withholding obligations7,783 shares$22,941.72 during the past three months is also disclosed.
Opus Genetics, Inc. received an updated ownership report from Perceptive Advisors LLC, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., stating beneficial ownership of 9,233,710 shares of Common Stock, representing 9.99% of the company’s Common Stock outstanding as of August 3, 2026.
The stake is held entirely through warrants. The Master Fund holds Pre-Funded Warrants to purchase 13,617,584 shares at $0.0001 per share and Common Warrants to purchase 13,157,895 shares at $0.95 per share. A Beneficial Ownership Limitation of 9.99% restricts warrant exercises so that, as of this amendment, only 9,233,710 underlying shares are treated as beneficially owned under Section 13(d). Perceptive Advisors acts as investment manager to the Master Fund, and Mr. Edelman is the managing member of Perceptive Advisors.
Caligan Partners LP and David Johnson report beneficial ownership of Opus Genetics, Inc. common stock on a passive Schedule 13G/A basis. They collectively report 6,077,084 shares of common stock, representing 7.3% of the class.
The ownership percentage is based on 83,195,823 shares of Opus Genetics common stock outstanding as of August 3, 2026, as reported by the company for the quarter ended June 30, 2026. All reported shares are held with shared voting and dispositive power through Caligan-managed funds and accounts.